DE69226739T2 - Arzneimittel enthaltend Protein-gebundende Liposome - Google Patents

Arzneimittel enthaltend Protein-gebundende Liposome

Info

Publication number
DE69226739T2
DE69226739T2 DE69226739T DE69226739T DE69226739T2 DE 69226739 T2 DE69226739 T2 DE 69226739T2 DE 69226739 T DE69226739 T DE 69226739T DE 69226739 T DE69226739 T DE 69226739T DE 69226739 T2 DE69226739 T2 DE 69226739T2
Authority
DE
Germany
Prior art keywords
containing protein
medicament containing
bound liposomes
residues
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69226739T
Other languages
English (en)
Other versions
DE69226739D1 (de
Inventor
Toshiaki Tagawa
Saiko Hosokawa
Kazuhiro Nagaike
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Chemical Corp
Original Assignee
Mitsubishi Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Chemical Corp filed Critical Mitsubishi Chemical Corp
Publication of DE69226739D1 publication Critical patent/DE69226739D1/de
Application granted granted Critical
Publication of DE69226739T2 publication Critical patent/DE69226739T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69226739T 1991-05-23 1992-05-20 Arzneimittel enthaltend Protein-gebundende Liposome Expired - Fee Related DE69226739T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11876291A JP3220180B2 (ja) 1991-05-23 1991-05-23 薬剤含有タンパク質結合リポソーム

Publications (2)

Publication Number Publication Date
DE69226739D1 DE69226739D1 (de) 1998-10-01
DE69226739T2 true DE69226739T2 (de) 1999-02-11

Family

ID=14744436

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69226739T Expired - Fee Related DE69226739T2 (de) 1991-05-23 1992-05-20 Arzneimittel enthaltend Protein-gebundende Liposome

Country Status (7)

Country Link
US (1) US5264221A (de)
EP (1) EP0526700B1 (de)
JP (1) JP3220180B2 (de)
AT (1) ATE170083T1 (de)
CA (1) CA2069244C (de)
DE (1) DE69226739T2 (de)
ES (1) ES2120972T3 (de)

Families Citing this family (324)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0720857B2 (ja) * 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5656211A (en) * 1989-12-22 1997-08-12 Imarx Pharmaceutical Corp. Apparatus and method for making gas-filled vesicles of optimal size
US6787153B1 (en) 1991-06-28 2004-09-07 Mitsubishi Chemical Corporation Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
CA2072249C (en) * 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
JP3351476B2 (ja) * 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
US6180134B1 (en) * 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
US6326353B1 (en) * 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
CA2137296C (en) * 1993-12-06 2001-10-16 Tsuyoshi Miyazaki Phospholipid derivative and reactive vesicle-forming agent
CA2137297C (en) * 1993-12-06 2000-04-18 Tsuyoshi Miyazaki Reactive vesicle and functional substance-fixed vesicle
US20010055581A1 (en) 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US6214388B1 (en) * 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5658588A (en) * 1995-03-31 1997-08-19 University Of Cincinnati Fibrinogen-coated liposomes
GB9509016D0 (en) * 1995-05-03 1995-06-21 Royal Free Hosp School Med Tissue entrapment
US6673364B1 (en) * 1995-06-07 2004-01-06 The University Of British Columbia Liposome having an exchangeable component
CA2279673A1 (en) * 1995-12-15 1997-06-16 Enzo Therapeutics, Inc. Property effecting and/or property exhibiting constructs for the expression of non-native nucleic acids for therapeutic and diagnostic uses
CA2202103C (en) 1996-04-11 2007-01-09 Toshiaki Tagawa Method for preparing closed vesicles
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US5919480A (en) * 1996-06-24 1999-07-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method
ES2208946T3 (es) * 1996-08-23 2004-06-16 Sequus Pharmaceuticals, Inc. Liposomas que contienen un compuesto de cisplatino.
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
EP0932390A1 (de) * 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Therapeutische liposomenzusammensetzung und verfahren
US6224903B1 (en) 1996-10-11 2001-05-01 Sequus Pharmaceuticals, Inc. Polymer-lipid conjugate for fusion of target membranes
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6528271B1 (en) 1997-06-05 2003-03-04 Duke University Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia
US5891646A (en) * 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
US7541151B2 (en) 1997-06-05 2009-06-02 Duke University Single-cell biosensor for the measurement of GPCR ligands in a test sample
KR19990029749A (ko) * 1997-09-17 1999-04-26 미우라 아끼라 2가 반응성 수용성 고분자 유도체 및 이들을 함유하는 복합체
US6734171B1 (en) 1997-10-10 2004-05-11 Inex Pharmaceuticals Corp. Methods for encapsulating nucleic acids in lipid bilayers
US6083923A (en) * 1997-10-31 2000-07-04 Isis Pharmaceuticals Inc. Liposomal oligonucleotide compositions for modulating RAS gene expression
US7229841B2 (en) * 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US6407218B1 (en) * 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
US6258774B1 (en) * 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
US6077709A (en) 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression
US20020114829A1 (en) * 1998-12-18 2002-08-22 Hayat Onyuksel Materials and methods for making improved liposome compositions
AU3191100A (en) * 1999-03-17 2000-10-04 Mitsubishi Chemical Corporation Ligand-bonded complex
US20050074499A1 (en) * 1999-03-17 2005-04-07 Mitsubishi Chemical Corporation Ligand-bonded complex
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
AU766570B2 (en) * 1999-04-23 2003-10-16 Mitsubishi Chemical Corporation Antibody and polyalkylene glycol-bonded liposome
GB9915074D0 (en) * 1999-06-28 1999-08-25 Cortecs Plc Ligand-binding composition
WO2001017568A2 (en) * 1999-09-07 2001-03-15 Conjuchem, Inc. Bioconjugation in vivo to pulmonary or blood components
US6261840B1 (en) 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US20020055479A1 (en) 2000-01-18 2002-05-09 Cowsert Lex M. Antisense modulation of PTP1B expression
US6680172B1 (en) 2000-05-16 2004-01-20 Regents Of The University Of Michigan Treatments and markers for cancers of the central nervous system
US7279324B2 (en) * 2001-01-23 2007-10-09 Duke University Nucleic acid encoding G-protein coupled receptor with modified DRY motif
EP1401376B1 (de) * 2001-04-30 2016-11-30 Cytimmune Sciences, Inc. Kolloidale metallzusammensetzungen und verfahren
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
ES2372321T3 (es) 2001-06-20 2012-01-18 Genentech, Inc. Composiciones y métodos para el diagnóstico y tratamiento de un tumor de pulmón.
EP2270024B1 (de) 2001-06-21 2018-10-24 Ionis Pharmaceuticals, Inc. Antisense-Modulation von Superoxid-Dismutase 1, Expression in Lösung
AUPR621501A0 (en) * 2001-07-06 2001-08-02 Commonwealth Scientific And Industrial Research Organisation Delivery of ds rna
JPWO2003010542A1 (ja) * 2001-07-25 2004-11-18 三菱ウェルファーマ株式会社 癌診断薬
US6964950B2 (en) 2001-07-25 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
US7425545B2 (en) 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
CA2454667A1 (en) * 2001-07-25 2003-02-26 Mitsubishi Pharma Corporation Remedies for mammary cancer
US20030096772A1 (en) 2001-07-30 2003-05-22 Crooke Rosanne M. Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
KR101008758B1 (ko) 2001-09-18 2011-01-14 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
EP2270231A3 (de) 2001-10-09 2011-04-27 ISIS Pharmaceuticals, Inc. Antisense Modulation der Expression von insulin-like growth factor binding protein 5
IL161733A0 (en) 2001-11-02 2005-11-20 Insert Therapeutics Inc Methods and compositions for therapeutic use of rna interference
US20050123532A1 (en) * 2001-12-04 2005-06-09 Takaharu Kouno Method of activating protein
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
KR100623128B1 (ko) 2002-01-02 2006-09-14 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
US20060193906A1 (en) * 2002-01-30 2006-08-31 National Institute Of Advanced Industrial Science And Technology Sugar-modified liposome and products comprising the liposome
US7070801B2 (en) * 2002-01-30 2006-07-04 National Institute Of Advanced Industrial Science And Technology Sugar-modified liposome and products comprising the liposome
US20030182669A1 (en) * 2002-03-19 2003-09-25 Rockman Howard A. Phosphoinositide 3-kinase mediated inhibition of GPCRs
US20030180712A1 (en) 2002-03-20 2003-09-25 Biostratum Ab Inhibition of the beta3 subunit of L-type Ca2+ channels
EP2011886A3 (de) 2002-04-16 2009-02-11 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
US7199107B2 (en) 2002-05-23 2007-04-03 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
US7290215B2 (en) * 2002-06-03 2007-10-30 Microsoft Corporation Dynamic wizard interface system and method
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
US20050196382A1 (en) * 2002-09-13 2005-09-08 Replicor, Inc. Antiviral oligonucleotides targeting viral families
KR101360955B1 (ko) * 2002-09-13 2014-02-10 레플리코르 인코포레이티드 비서열 상보적 항바이러스 올리고뉴클레오티드
EP1549767A4 (de) 2002-09-26 2006-06-07 Amgen Inc Modulation der expression von forkhead-box o1a
EP1559725A4 (de) 2002-10-04 2005-12-14 Mitsubishi Pharma Corp Antikörper mit antigenerkennung
WO2004044132A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Modified oligonucleotides for use in rna interference
EP1560839A4 (de) 2002-11-05 2008-04-23 Isis Pharmaceuticals Inc Chimäre oligomere verbindungen und derenverwendung in der genmodulation
WO2004044181A2 (en) 2002-11-13 2004-05-27 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein b expression
EP2336319A1 (de) 2002-11-13 2011-06-22 Genzyme Corporation Antisense-Modulation von Apolipoprotein-B-Expression
US20050158375A1 (en) * 2002-11-15 2005-07-21 Toshikiro Kimura Pharmaceutical composition containing liposomes for treating cancer
CN1711074B (zh) * 2002-11-15 2010-10-06 尼普洛株式会社 脂质体
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
DE60327715D1 (de) * 2002-12-20 2009-07-02 Mitsubishi Tanabe Pharma Corp Verfahren zum schutz von thiolgruppen in antikörpern
US7468356B2 (en) 2003-02-11 2008-12-23 Antisense Therapeutics Ltd. Modulation of insulin like growth factor I receptor expression
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
CA2522184A1 (en) * 2003-04-17 2004-11-04 The Trustees Of Columbia University In The City Of New York Desmoglein 4 is a novel gene involved in hair growth
US7399853B2 (en) 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
BRPI0410886A (pt) 2003-06-03 2006-07-04 Isis Pharmaceuticals Inc composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
CA2539181A1 (en) 2003-09-18 2005-03-31 Isis Pharmaceuticals, Inc. Modulation of eif4e expression
US20050074453A1 (en) * 2003-10-02 2005-04-07 Ferree Bret A. Methods of preventing adhesions following laminectomies and other surgical procedures
CA2541438C (en) 2003-10-10 2013-11-26 Meditech Research Limited The modulation of hyaluronan synthesis and degradation in the treatment of disease
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
ES2472690T3 (es) 2003-11-17 2014-07-02 Genentech, Inc. Anticuerpo contra CD22 para el tratamiento de tumores de origen hematopoy�tico
JP2008504216A (ja) 2003-12-02 2008-02-14 サイトイミューン サイエンシズ インコーポレイテッド モノクローナル抗体の生成のための方法および組成物
EP1711606A2 (de) 2004-01-20 2006-10-18 Isis Pharmaceuticals, Inc. Modulation der expression des glucocorticoidrezeptors
US7468431B2 (en) 2004-01-22 2008-12-23 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP2 expression
EP1715971A4 (de) * 2004-01-28 2010-10-13 Cytimmune Sciences Inc Funktionalisierte kolloidale metallzusammensetzungen und verfahren
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
EP2899278A1 (de) * 2004-03-12 2015-07-29 Alnylam Pharmaceuticals Inc. iRNS-Wirkstoffe für VEGF-Targeting
US8790919B2 (en) 2004-03-15 2014-07-29 Isis Pharmaceuticals, Inc. Compositions and methods for optimizing cleavage of RNA by RNase H
EP1579850A3 (de) * 2004-03-15 2009-12-16 Nipro Corporation Pharmazeutische Zubereitung mit Lipsomen zur Behandlung von Krebs
WO2005089448A2 (en) * 2004-03-18 2005-09-29 Transave, Inc. Administration of cisplatin by inhalation
DK1730280T3 (en) * 2004-03-26 2019-02-04 Curis Inc RNA interference modulators for hedgehog signaling and applications thereof
US20050244869A1 (en) 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
US20060034906A1 (en) * 2004-05-21 2006-02-16 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
US20090048192A1 (en) * 2004-06-03 2009-02-19 Isis Pharmaceuticals, Inc. Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
JP4692983B2 (ja) 2004-07-12 2011-06-01 独立行政法人科学技術振興機構 リポソーム封入物質がエンドソームから脱出可能なリポソーム
US7709539B2 (en) * 2004-08-11 2010-05-04 Chang Gung University Therapeutic use of resveratrol for hyperglycemia
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
JP5101288B2 (ja) 2004-10-05 2012-12-19 カリフォルニア インスティテュート オブ テクノロジー アプタマー調節される核酸及びその利用
WO2006055352A2 (en) * 2004-11-08 2006-05-26 Transave, Inc. Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
AU2006213686A1 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
EP2382996B1 (de) 2005-02-18 2015-01-14 The University of Tokushima Lipidfilmstruktur enthaltend ein Polyoxyalkylenkettenhaltiges Lipidderivat
RU2007137489A (ru) 2005-03-10 2009-04-20 Дженентек, Инк. (Us) Способы и композиции для модуляции целостности сосудов
JPWO2006101201A1 (ja) 2005-03-24 2008-09-04 国立大学法人 北海道大学 目的物質を効率的に核内に送達可能なリポソーム
JP2008537551A (ja) 2005-03-31 2008-09-18 カランド ファーマシューティカルズ， インコーポレイテッド リボヌクレオチドレダクターゼサブユニット２の阻害剤およびその使用
BRPI0613185A2 (pt) * 2005-04-29 2010-12-21 Univ Louisville Res Found revestimento de superfìcie celular com agentes ativos
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
WO2007049731A1 (ja) 2005-10-28 2007-05-03 Mitsubishi Tanabe Pharma Corporation 新規細胞膜透過ペプチド
EP2202239A1 (de) 2005-11-01 2010-06-30 Alnylam Pharmaceuticals Inc. RNAi-Hemmung von Influenza-Virus-Neubildungen
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007056264A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
JP2009516710A (ja) 2005-11-21 2009-04-23 アイシス ファーマシューティカルズ， インコーポレーテッド ｅＩＦ４Ｅ−ＢＰ２の発現のモジュレート
CA2638908C (en) 2006-01-26 2021-04-27 Susan M. Freier Compositions and their uses directed to huntingtin
US8229398B2 (en) * 2006-01-30 2012-07-24 Qualcomm Incorporated GSM authentication in a CDMA network
WO2007093594A1 (en) * 2006-02-14 2007-08-23 Novo Nordisk Health Care Ag Coupling of polypeptides at the c-terminus
NZ571568A (en) 2006-03-31 2010-11-26 Alnylam Pharmaceuticals Inc Double-stranded RNA molecule compositions and methods for inhibiting expression of Eg5 gene
WO2007126455A2 (en) 2006-04-05 2007-11-08 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
WO2007127919A2 (en) * 2006-04-28 2007-11-08 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a gene from the jc virus
EP2013344B1 (de) 2006-05-03 2012-08-29 Baltic Technology Development, Ltd. Antisense-agentien mit kombination von mit stark gebundener base modifiziertem oligonukleotid und künstlicher nuklease
EP2392583A1 (de) * 2006-05-19 2011-12-07 Alnylam Europe AG. RNAi-Modulation von AHA und therapeutische Verwendungen davon
CA2653451C (en) * 2006-05-22 2015-12-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of ikk-b gene
US8598333B2 (en) * 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
US8048448B2 (en) * 2006-06-15 2011-11-01 Abbott Cardiovascular Systems Inc. Nanoshells for drug delivery
JP2008031142A (ja) * 2006-06-29 2008-02-14 Hokkaido Univ 脂肪組織標的化ペプチド及び該ペプチドを有するリポソーム
US8198253B2 (en) 2006-07-19 2012-06-12 Isis Pharmaceuticals, Inc. Compositions and their uses directed to HBXIP
US8158595B2 (en) 2006-11-09 2012-04-17 California Institute Of Technology Modular aptamer-regulated ribozymes
EP2090305A4 (de) * 2006-12-08 2012-12-26 Katayama Chemical Ind Co Ltd Liposom mit eingekapseltem ammin-platin-komplex von hoher konzentration und verfahren zur herstellung des liposoms
WO2008086807A2 (en) * 2007-01-19 2008-07-24 Exiqon A/S Mediated cellular delivery of lna oligonucleotides
EP2114981B1 (de) 2007-01-29 2013-05-08 Isis Pharmaceuticals, Inc. Verbindungen und Methoden zur Modulation der Proteinexpression
ES2379413T3 (es) 2007-02-22 2012-04-25 Genentech, Inc. Procedimientos para detectar la enfermedad inflamatoria del intestino
US7759320B2 (en) 2007-03-29 2010-07-20 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a gene from the Ebola
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
US20090082217A1 (en) * 2007-07-16 2009-03-26 California Institute Of Technology Selection of nucleic acid-based sensor domains within nucleic acid switch platform
US8367815B2 (en) * 2007-08-28 2013-02-05 California Institute Of Technology Modular polynucleotides for ligand-controlled regulatory systems
US20120165387A1 (en) 2007-08-28 2012-06-28 Smolke Christina D General composition framework for ligand-controlled RNA regulatory systems
US8865667B2 (en) * 2007-09-12 2014-10-21 California Institute Of Technology Higher-order cellular information processing devices
CA2700378A1 (en) * 2007-09-21 2009-03-29 Cytimmune Sciences, Inc. Nanotherapeutic colloidal metal compositions and methods
US20110014118A1 (en) * 2007-09-21 2011-01-20 Lawrence Tamarkin Nanotherapeutic colloidal metal compositions and methods
AU2008307482B2 (en) 2007-10-02 2012-07-12 Amgen Inc. Increasing erythropoietin using nucleic acids hybridizable to micro-RNA and precursors thereof
US7960145B2 (en) * 2007-11-08 2011-06-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
JP5530933B2 (ja) 2007-12-10 2014-06-25 アルナイラム ファーマシューティカルズ， インコーポレイテッド 第ｖｉｉ因子遺伝子発現阻害のための組成物及び方法
US9029524B2 (en) * 2007-12-10 2015-05-12 California Institute Of Technology Signal activated RNA interference
WO2009100351A2 (en) * 2008-02-08 2009-08-13 Alnylam Pharmaceuticals, Inc. Delivery of rnai constructs to oligodendrocytes
AU2009221775B2 (en) * 2008-03-05 2015-05-07 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of Eg5 and VEGF genes
EP2283133A2 (de) 2008-04-04 2011-02-16 Calando Pharmaceuticals, Inc. Zusammensetzungen und verwendung von epas1-inhibitoren
US20110076296A1 (en) 2008-04-25 2011-03-31 Innate Pharma S.A. TLR3 Agonist Compositions
WO2009148169A1 (ja) * 2008-06-06 2009-12-10 片山化学工業株式会社 アンミン白金錯体を高濃度に内包するリポソームを用いた腫瘍治療技術
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
KR101877698B1 (ko) 2008-08-25 2018-07-12 엑스칼리아드 파마슈티컬즈, 인코포레이티드 결합 조직 성장 인자에 대한 안티센스 올리고뉴클레오타이드 및 그의 용도
WO2010028054A1 (en) 2008-09-02 2010-03-11 Alnylam Europe Ag. Compositions and methods for inhibiting expression of mutant egfr gene
US8664189B2 (en) 2008-09-22 2014-03-04 Rxi Pharmaceuticals Corporation RNA interference in skin indications
CA2739170A1 (en) 2008-09-25 2010-04-01 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
ES2656516T3 (es) 2008-10-20 2018-02-27 Alnylam Pharmaceuticals, Inc. Composiciones y métodos para inhibir la expresión de transtiretina
US20110230399A1 (en) * 2008-11-25 2011-09-22 Bowen Richard L Methods for Treating Obesity Related Disease
MX366774B (es) 2008-12-04 2019-07-24 Curna Inc Uso de oligonucleótidos antisentido en la inhibición de transcrito antisentido natural para sirtuina 1.
RU2620970C2 (ru) 2008-12-04 2017-05-30 КьюРНА,Инк., Лечение связанных с эритропоэтином (еро) заболеваний путем ингибирования природного антисмыслового транскрипта к еро
KR101866152B1 (ko) 2008-12-04 2018-06-08 큐알엔에이, 인크. 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
AU2009324534B2 (en) 2008-12-10 2015-07-30 Alnylam Pharmaceuticals, Inc. GNAQ targeted dsRNA compositions and methods for inhibiting expression
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
ES2658626T3 (es) 2009-02-12 2018-03-12 Curna, Inc. Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de células gliales (GDNF) por inhibición de transcrito antisentido natural a GDNF
EP2396038B1 (de) 2009-02-12 2015-10-21 CuRNA, Inc. Behandlung von erkrankungen im zusammenhang mit dem brain-derived neurotrophen faktor (bdnf) mittels hemmung des natürlichen antisense-transkripts gegen bdnf
US8329882B2 (en) 2009-02-18 2012-12-11 California Institute Of Technology Genetic control of mammalian cells with synthetic RNA regulatory systems
WO2010099341A1 (en) 2009-02-26 2010-09-02 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of mig-12 gene
EP2963116B1 (de) 2009-03-04 2020-11-11 CuRNA, Inc. Behandlung von sirtuin 1 (sirt1)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirt 1
CN102421900B (zh) 2009-03-12 2015-07-22 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因表达的脂质配制的组合物以及方法
ES2656290T3 (es) 2009-03-16 2018-02-26 Curna, Inc. Tratamiento de enfermedades relacionadas con el factor nuclear (derivado de eritroide 2) similar al 2 (NRF2) mediante inhibición del transcrito antisentido natural a NRF2
WO2010107740A2 (en) 2009-03-17 2010-09-23 Curna, Inc. Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
US9145555B2 (en) 2009-04-02 2015-09-29 California Institute Of Technology Integrated—ligand-responsive microRNAs
EP3524275A1 (de) 2009-04-22 2019-08-14 Massachusetts Institute Of Technology Angeborene immununterdrückung ermöglicht die wiederholte verabreichung von langen rna-molekülen
EP2424987B1 (de) 2009-05-01 2017-11-15 CuRNA, Inc. Behandlung von hämoglobin (hbf / hbg) verwandten krankheiten durch die inhibition des natürlichen antisense transcripts zu hbf / hbg
US20120046236A1 (en) 2009-05-06 2012-02-23 Opko Curna Llc Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
US9155754B2 (en) 2009-05-06 2015-10-13 Curna, Inc. Treatment of ABCA1 gene related diseases by inhibition of a natural antisense transcript to ABCA1
KR101749356B1 (ko) 2009-05-18 2017-07-06 큐알엔에이, 인크. 재편성 인자에 대한 천연 안티센스 전사체의 억제에 의한 재편성 인자 관련된 질환의 치료
EP2432882B1 (de) 2009-05-22 2019-12-25 CuRNA, Inc. Behandlung von erkrankungen im zusammenhang mit dem transkriptionsfaktor e3 (tfe3) und dem insulinrezeptorsubstrat 2 (irs2) mittels hemmung des natürlichen antisense-transkripts gegen tfe3
WO2010138806A2 (en) 2009-05-28 2010-12-02 Curna, Inc. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
CA2765700C (en) 2009-06-16 2021-01-05 Opko Curna, Llc Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
EP2443238B1 (de) 2009-06-16 2017-03-22 CuRNA, Inc. Behandlung von erkrankungen im zusammenhang mit paraoxonase 1 (pon1) mittels hemmung des natürlichen antisense-transkripts gegen pon 1
JP6073133B2 (ja) 2009-06-24 2017-02-01 クルナ・インコーポレーテッド 腫瘍壊死因子受容体２（ｔｎｆｒ２）に対する天然アンチセンス転写物の抑制によるｔｎｆｒ２関連疾患の治療
KR101807324B1 (ko) 2009-06-26 2017-12-08 큐알엔에이, 인크. 다운 증후군 유전자에 대한 천연 안티센스 전사체의 억제에 의한 다운 증후군 유전자 관련된 질환의 치료
JP6128848B2 (ja) 2009-08-05 2017-05-17 クルナ・インコーポレーテッド インスリン遺伝子（ｉｎｓ）に対する天然アンチセンス転写物の抑制によるインスリン遺伝子（ｉｎｓ）関連疾患の治療
AP3574A (en) 2009-08-14 2016-02-08 Alnylam Pharmaceuticals Inc Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
WO2011031482A2 (en) 2009-08-25 2011-03-17 Curna, Inc. Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
JP5887270B2 (ja) 2009-09-02 2016-03-16 ジェネンテック， インコーポレイテッド 突然変異体ｓｍｏｏｔｈｅｎｅｄおよびその使用方法
EP3252068A3 (de) 2009-10-12 2018-03-14 Larry J. Smith Verfahren und zusammensetzungen zur modulation der genexpression unter verwendung in-vivo- oder in-vitro-verabreichten arzneistoffen auf oligonukleotidbasis
ES2564207T3 (es) 2009-10-22 2016-03-18 F. Hoffmann-La Roche Ag Métodos y composiciones para modular la activación con hepsina de la proteína estimuladora de macrófagos
US20120244169A1 (en) 2009-11-06 2012-09-27 Fibrogen, Inc. Treatment for Radiation-Induced Disorders
EP3002297B1 (de) 2009-11-30 2020-04-08 F. Hoffmann-La Roche AG Antikörper zur behandlung und der diagnose slc34a2 (tat211) exprimierender tumore.
CN104529945A (zh) 2009-12-11 2015-04-22 基因密码公司 使用gdnf家族配体(gfl)模拟剂或ret信号传导通路活化剂促进神经细胞存活的方法
US9173895B2 (en) 2009-12-16 2015-11-03 Curna, Inc. Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1
CA2782375C (en) 2009-12-23 2023-10-31 Opko Curna, Llc Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
WO2011079261A2 (en) 2009-12-23 2011-06-30 Curna, Inc. Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
WO2011090741A2 (en) 2009-12-29 2011-07-28 Opko Curna, Llc TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
JP5993744B2 (ja) 2009-12-29 2016-09-14 カッパーアールエヌエー，インコーポレイテッド 核呼吸因子１（ｎｒｆ１）に対する天然アンチセンス転写物の阻害による核呼吸因子１関連疾患の治療
US8946181B2 (en) 2010-01-04 2015-02-03 Curna, Inc. Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8
US8912157B2 (en) 2010-01-06 2014-12-16 Curna, Inc. Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
RU2611191C2 (ru) 2010-01-11 2017-02-21 Курна, Инк. Лечение заболеваний, связанных со связывающим половые гормоны глобулином (гспг), путем ингибирования природного антисмыслового транскрипта к гспг
WO2011090971A2 (en) 2010-01-19 2011-07-28 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for male reproductive disorders
JP5981850B2 (ja) 2010-01-25 2016-08-31 カッパーアールエヌエー，インコーポレイテッド ＲＮａｓｅＨ１に対する天然アンチセンス転写物の阻害によるＲＮａｓｅＨ１関連疾患の治療
CN102844435B (zh) 2010-02-22 2017-05-10 库尔纳公司 通过抑制吡咯啉‑5‑羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病
KR20130004579A (ko) 2010-02-23 2013-01-11 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CA2792291A1 (en) 2010-03-29 2011-10-06 Kumamoto University Sirna therapy for transthyretin (ttr) related ocular amyloidosis
JP2013523162A (ja) 2010-04-06 2013-06-17 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｃｄ２７４／ｐｄ−ｌ１遺伝子の発現を阻害するための組成物および方法
TWI644675B (zh) 2010-04-09 2018-12-21 可娜公司 藉由抑制纖維母細胞生長因子２１（ｆｇｆ２１）之天然反義轉錄物以治療ｆｇｆ２１相關疾病
WO2011132713A1 (ja) 2010-04-21 2011-10-27 国立大学法人北海道大学 核内移行性を有する脂質膜構造体
NZ603339A (en) 2010-04-29 2015-01-30 Isis Pharmaceuticals Inc Modulation of transthyretin expression
KR101992076B1 (ko) 2010-05-03 2019-06-21 큐알엔에이, 인크. 시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료
RU2636461C2 (ru) 2010-05-03 2017-11-23 Дженентек, Инк. Композиции и способы для диагностики и лечения опухоли
EP2569430B1 (de) 2010-05-12 2018-10-17 The Trustees of Columbia University in the City of New York Verfahren zur herstellung enteroendokriner zellen zur produktion und abgabe von insulin
TWI531370B (zh) 2010-05-14 2016-05-01 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
EP3299464B1 (de) 2010-05-26 2019-10-02 CuRNA, Inc. Behandlung von durch atonal homolog 1 (atoh1) vermittelten erkrankungen durch hemmung des natürlichen antisense-transkripts für atoh1
WO2011153323A2 (en) 2010-06-02 2011-12-08 Alnylam Pharmaceuticals, Inc. Compositions and methods directed to treating liver fibrosis
NO2593547T3 (de) 2010-07-14 2018-04-14
DK2625197T3 (en) 2010-10-05 2016-10-03 Genentech Inc Smoothened MUTANT AND METHODS OF USING THE SAME
CA2813901C (en) 2010-10-06 2019-11-12 Curna, Inc. Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
US9222088B2 (en) 2010-10-22 2015-12-29 Curna, Inc. Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
US20130210893A1 (en) 2010-10-27 2013-08-15 Curna, Inc. Treatment of interferon-related developmental regulator 1 (ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1
WO2012061811A2 (en) 2010-11-05 2012-05-10 Fibrogen, Inc. Treatment method for lung remodeling diseases
CN103370054A (zh) 2010-11-09 2013-10-23 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
CA2817712C (en) 2010-11-12 2020-03-24 Georgetown University Immortalization of epithelial cells and methods of use
JP6071893B2 (ja) 2010-11-23 2017-02-01 カッパーアールエヌエー，インコーポレイテッド Ｎａｎｏｇへの天然アンチセンス転写物の阻害によるｎａｎｏｇ関連疾患の治療
EP2649182A4 (de) 2010-12-10 2015-05-06 Alnylam Pharmaceuticals Inc Zusammensetzungen und verfahren zur erhöhung einer erythropoietin (epo)-herstellung
EP2648763A4 (de) 2010-12-10 2014-05-14 Alnylam Pharmaceuticals Inc Zusammensetzungen und verfahren zur expressionshemmung der gene klf-1 und bcl11a
MX365647B (es) 2011-02-02 2019-06-10 Excaliard Pharmaceuticals Inc El uso de compuestos antisentido dirigidos al factor de crecimiento del tejido conectivo (ctgf) para tratar queloides o cicatrices hipertroficas.
WO2012109495A1 (en) 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
MX343008B (es) 2011-03-29 2016-10-21 Alnylam Pharmaceuticals Inc Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6).
US10086043B2 (en) 2011-04-03 2018-10-02 The General Hospital Corporation Efficient protein expression in vivo using modified RNA (MOD-RNA)
CA2832972C (en) 2011-04-13 2019-04-30 Isis Pharmaceuticals, Inc. Antisense modulation of ptp1b expression
WO2012166903A1 (en) 2011-06-02 2012-12-06 President And Fellows Of Harvard College Methods and uses for ex vivo tissue culture systems
US9593330B2 (en) 2011-06-09 2017-03-14 Curna, Inc. Treatment of frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CA2839437A1 (en) 2011-06-16 2012-12-20 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
CA3191066A1 (en) 2011-06-21 2012-12-27 Alnylam Pharmaceuticals Inc. Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes
WO2012177949A2 (en) 2011-06-21 2012-12-27 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of expression of protein c (proc) genes
WO2012177906A1 (en) 2011-06-21 2012-12-27 Alnylam Pharmaceuticals, Inc. Assays and methods for determining activity of a therapeutic agent in a subject
EP3597750B1 (de) 2011-06-23 2022-05-04 Alnylam Pharmaceuticals, Inc. Serpina1-sirnas: materialzusammensetzungen und behandlungsverfahren
AU2012275841A1 (en) 2011-06-27 2014-01-16 The Jackson Laboratory Methods and compositions for treatment of cancer and autoimmune disease
WO2013019857A2 (en) 2011-08-01 2013-02-07 Alnylam Pharmaceuticals, Inc. Method for improving the success rate of hematopoietic stem cell transplants
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP3401401B1 (de) 2011-09-20 2020-04-15 Ionis Pharmaceuticals, Inc. Antisense-modulation der gcgr-expression
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
IN2014CN03749A (de) 2011-10-25 2015-09-25 Isis Pharmaceuticals Inc
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
WO2013138374A2 (en) 2012-03-15 2013-09-19 Curna, Inc. Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
US9133461B2 (en) 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
WO2014039533A2 (en) 2012-09-04 2014-03-13 Eleison Pharmaceuticals, Llc Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
US20160136159A1 (en) 2012-09-17 2016-05-19 Chemedest Ltd. Method for Treating Peripheral Neuropathy
CN102920658B (zh) * 2012-11-02 2015-01-21 艾韦特(溧阳)医药科技有限公司 与glp-1类似物和聚乙二醇结合的脂质体及其制备方法
WO2014130922A1 (en) 2013-02-25 2014-08-28 Trustees Of Boston University Compositions and methods for treating fungal infections
WO2014152497A2 (en) 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for cognitive disorders
WO2014160871A2 (en) 2013-03-27 2014-10-02 The General Hospital Corporation Methods and agents for treating alzheimer's disease
TW201515650A (zh) 2013-05-06 2015-05-01 艾爾妮蘭製藥公司 遞送經脂質調配之核酸分子之劑量及方法
DK3007704T3 (da) 2013-06-13 2021-03-29 Antisense Therapeutics Ltd Kombinationsterapi til akromegali
WO2015035231A1 (en) 2013-09-05 2015-03-12 Sarepta Therapeutics, Inc. Antisense-induced exon2 inclusion in acid alpha-glucosidase
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10036020B2 (en) 2013-09-19 2018-07-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for inhibiting JC virus (JCV)
MX2016004230A (es) 2013-10-02 2016-10-21 Alnylam Pharmaceuticals Inc Composiciones y metodos para inhibir la expresion del gen lect2.
SG10201910929QA (en) 2013-10-04 2020-01-30 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of the alas1 gene
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
JP2017500865A (ja) 2013-12-19 2017-01-12 ノバルティス アーゲー レプチンｍＲＮＡの組成物および製剤
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
JP6736467B2 (ja) 2014-02-04 2020-08-05 ジェネンテック， インコーポレイテッド 平滑化変異体及びその使用方法
WO2015171918A2 (en) 2014-05-07 2015-11-12 Louisiana State University And Agricultural And Mechanical College Compositions and uses for treatment thereof
CA2985344A1 (en) 2014-06-26 2015-12-30 The Trustees Of Columbia University In The City Of New York Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
WO2016033424A1 (en) 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
EP3226889A4 (de) 2014-11-19 2018-11-21 The Trustees of Columbia University in the City of New York Osteocalcin zur behandlung von gebrechlichkeit im zusammenhang mit alterung
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
AU2015364508A1 (en) 2014-12-18 2017-07-06 Alnylam Pharmaceuticals, Inc. ReversirTM compounds
EP3247386A4 (de) 2015-01-20 2018-10-03 The Children's Medical Center Corporation Anti-net-verbindungen zur behandlung und prävention von fibrose und wundheilungsförderung
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3302497A4 (de) 2015-06-01 2019-01-16 Sarepta Therapeutics, Inc. Antisense-induszierte exonexklusion in typ-vii-kollagen
JP6768722B2 (ja) 2015-07-02 2020-10-14 大塚製薬株式会社 凍結乾燥医薬組成物
CA2989970A1 (en) 2015-07-17 2017-01-26 Alnylam Pharmaceuticals, Inc. Multi-targeted single entity conjugates
TW201718857A (zh) 2015-09-14 2017-06-01 艾爾妮蘭製藥公司 用於抑制alas1基因表現之組合物及方法
US10954300B2 (en) 2015-09-28 2021-03-23 The Trustees Of Columbia University In The City Of New York Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
MA45819A (fr) 2015-10-09 2018-08-15 Sarepta Therapeutics Inc Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés
WO2017075670A1 (en) 2015-11-05 2017-05-11 Children's Hospital Los Angeles "mobilizing leukemia cells"
US11534451B2 (en) 2015-12-23 2022-12-27 Repluca Pty Ltd Nucleic acid oligomers and uses therefor
JP7040774B2 (ja) 2016-03-01 2022-03-23 マックォーリー・ユニバーシティ 神経学的症状の治療のためのリン酸化ｔａｕ及びｐ３８ガンマの使用
EP3445405A4 (de) 2016-04-18 2019-12-18 Sarepta Therapeutics, Inc. Antisense-oligomere und verfahren zur verwendung davon zur behandlung von erkrankungen in zusammenhang mit dem saure-alpha-glucosidase-gen
WO2018209288A1 (en) 2017-05-12 2018-11-15 Massachusetts Institute Of Technology Argonaute protein-double stranded rna complexes and uses related thereto
CA3067192A1 (en) 2017-06-15 2018-12-20 National University Corporation Hokkaido University Lipid membrane structure for delivery into sirna cell
US10590416B2 (en) 2017-07-06 2020-03-17 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of alpha-ENaC and methods of use
JP2020529409A (ja) 2017-08-03 2020-10-08 大塚製薬株式会社 薬物化合物およびその精製方法
WO2019055460A1 (en) 2017-09-13 2019-03-21 The Children's Medical Center Corporation COMPOSITIONS AND METHODS FOR THE TREATMENT OF TRANSPOSON-ASSOCIATED DISEASES
JP7394753B2 (ja) 2017-10-18 2023-12-08 サレプタ セラピューティクス， インコーポレイテッド アンチセンスオリゴマー化合物
CN116536272A (zh) 2018-04-06 2023-08-04 儿童医疗中心有限公司 用于体细胞重新编程和调整印记的组合物和方法
KR20210006353A (ko) 2018-05-04 2021-01-18 톨리스 상피 세포 및 골수 세포 모두를 활성화시키는 tlr3 리간드
WO2020037125A1 (en) 2018-08-16 2020-02-20 Alnylam Pharmaceuticals Inc. Compositions and methods for inhibiting expression of the lect2 gene
CN113454216A (zh) 2018-11-29 2021-09-28 旗舰先锋创新V股份有限公司 调节rna的方法
JP2022546570A (ja) 2019-09-03 2022-11-04 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｌｅｃｔ２遺伝子の発現を阻害するための組成物および方法
WO2021067747A1 (en) 2019-10-04 2021-04-08 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing ugt1a1 gene expression
WO2021087325A1 (en) 2019-11-01 2021-05-06 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajb1-prkaca fusion gene expression
TW202140786A (zh) 2020-02-10 2021-11-01 美商艾爾妮蘭製藥公司 用於靜默ｖｅｇｆ－ａ表現之組合物及方法
US20230190785A1 (en) 2020-03-30 2023-06-22 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajc15 gene expression
US20230295622A1 (en) 2020-04-06 2023-09-21 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing myoc expression
EP4133079A1 (de) 2020-04-07 2023-02-15 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur ausschaltung der scn9a-expression
US20230183707A1 (en) 2020-05-21 2023-06-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting marc1 gene expression
CA3214540A1 (en) 2021-04-22 2022-10-27 Pasi A. Janne Compositions and methods for treating cancer
WO2023283403A2 (en) 2021-07-09 2023-01-12 Alnylam Pharmaceuticals, Inc. Bis-rnai compounds for cns delivery
WO2024059165A1 (en) 2022-09-15 2024-03-21 Alnylam Pharmaceuticals, Inc. 17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4429008B1 (en) * 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
US4847080A (en) * 1984-03-07 1989-07-11 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipide vesicle carriers
US5059421A (en) * 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US5000960A (en) * 1987-03-13 1991-03-19 Micro-Pak, Inc. Protein coupling to lipid vesicles
JPH0720857B2 (ja) * 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
GB8824593D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2072249C (en) * 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane

Also Published As

Publication number Publication date
EP0526700A3 (de) 1994-01-26
CA2069244A1 (en) 1992-11-24
CA2069244C (en) 2002-10-01
EP0526700A2 (de) 1993-02-10
ATE170083T1 (de) 1998-09-15
US5264221A (en) 1993-11-23
EP0526700B1 (de) 1998-08-26
JP3220180B2 (ja) 2001-10-22
JPH04346918A (ja) 1992-12-02
ES2120972T3 (es) 1998-11-16
DE69226739D1 (de) 1998-10-01

Similar Documents

Publication Publication Date Title
DE69226739T2 (de) Arzneimittel enthaltend Protein-gebundende Liposome
DE68915001T2 (de) Liposome.
MX9203480A (es) Formulaciones medicinales en aereosol.
DE68911473D1 (de) Arzneimittelformulierungen.
DE68912232T2 (de) Konjugate zytotoxischer Arzneimittel.
DE68927501D1 (de) Saugdüse
NO172097C (no) Utleveringsinnretning for drikkevarer
FI930270A0 (fi) Cefalosporiner och homologer, framstaellningsfoerfaranden samt farmaceutiska kompositioner
DE3882157D1 (de) Nichtsteroide antientzuendungswirkstoffe enthaltende pharmazeutische zubereitungen.
DE3682960D1 (de) Pharmazeutische praeparate.
FI900636A0 (fi) Permeationsoekande aemne innefattande etanol och glycerinmonooleat.
DE3791053T1 (de) Vakuum-molekularpumpe
DE69013557D1 (de) An Liposome gekuppelte bioaktive Verbindungen und ihre Verwendung in pharmazeutischen Zubereitungen.
FI895268A0 (fi) Optiskt aktiva bensoxaziner och bensotiaziner och foerfarande foer deras stereospecifik framstaellning.
DE59309355D1 (de) Neue Phospholipidderivate
FI893366A0 (fi) 4-piperidylmetyl-2,3-dihydro-1h -isoindol- och 2,3,4,5-tetrahydro-1h-bensasepinderivat, deras framstaellning och terapeutiska anvaendning.
DE3891201T1 (de) Vakuum-molekularpumpe
FI912043A0 (fi) Pump foer automatisk och laongsam utstroemning fraon en laekemedelflaska.
DK52590D0 (da) Afgivelseslukke
IT8819790A0 (it) Peptidi ad attivita' farmaceutica.
ES1007934Y (es) Ventosa perfeccionada.
DE3770939D1 (de) Xylometazolinhaltige pharmazeutische praeparate.
ATE94382T1 (de) Adhaesives mittel zur arzneistoffabgabe.
FI885551A0 (fi) Skalningsmaskin och en daermed skalad produkt.
NO913298L (no) Terapeutisk aerosolpreparater.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee